Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical compositions comprising GLP-1 peptides or exendin-4 and a basal insulin peptide

A GLP-1, insulin peptide technology, applied in drug combinations, insulin, hormone peptides, etc., can solve problems such as slow onset and prolonged efficacy

Inactive Publication Date: 2010-10-13
NOVO NORDISK AS
View PDF11 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Some commercially available insulin formulations are characterized by a rapid onset of action, while others have a relatively slow onset of action but show a more or less prolonged efficacy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical compositions comprising GLP-1 peptides or exendin-4 and a basal insulin peptide
  • Pharmaceutical compositions comprising GLP-1 peptides or exendin-4 and a basal insulin peptide
  • Pharmaceutical compositions comprising GLP-1 peptides or exendin-4 and a basal insulin peptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach 1

[0184] Embodiment 1: A soluble pharmaceutical composition for parenteral administration comprising an insulinotropic GLP-1 compound, a basal insulin peptide, a pharmaceutically acceptable additive and zinc, wherein the zinc content is at least 5 Zn ions / 6 insulin molecular.

Embodiment approach 2

[0185] Embodiment 2: A soluble pharmaceutical composition for parenteral administration according to embodiment 1, comprising an insulinotropic GLP-1 compound, a basal insulin peptide, a pharmaceutically acceptable additive and zinc, wherein the zinc content is at least 6 zinc ion / 6 insulin molecules.

Embodiment approach 3

[0186] Embodiment 3: The pharmaceutical composition according to embodiment 1, wherein the zinc content is 5-16 zinc ions / 6 insulin molecules.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Pharmaceutical composition for parenteral administration comprising a basal insulin peptide and an insulinotropic GLP-1 peptide comprising at least 6 zinc atoms per 6 insulin molecules.

Description

field of invention [0001] The present invention relates to the field of pharmaceutical compositions. More specifically, the present invention relates to pharmaceutical compositions containing two different pharmaceutically active peptides. Background technique [0002] Diabetes mellitus is a metabolic disease in which the ability to utilize glucose is partially or completely lost. Since the introduction of insulin in the 1920s, there have been continuous efforts to improve the treatment of diabetes. With decades of chronic treatment for diabetic patients, there is a great need for insulin formulations that are safe, convenient and improve quality of life. [0003] In the treatment of diabetes, many different insulin formulations have been proposed and used, such as regular insulin, protamine zinc insulin (expressed as NPH), insulin zinc suspension (such as Semilente 、Lente and Ultralente ) and biphasic protamine zinc insulin. Some commercially available insulin form...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/605C07K14/62
CPCC07K14/62A61K38/00C07K14/605A61K38/26A61K38/28A61K47/02A61K47/12A61K47/183A61K2300/00A61P3/04A61P43/00A61P3/10
Inventor A·普卢姆D·B·斯蒂恩斯加尔德J·K·汤姆森M·施莱因A·S·K·马库森C·波尔森
Owner NOVO NORDISK AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com